So just to kind of level set, so DUO-E was a randomized phase three placebo-controlled trial that was looking to add immuno-oncology agent Durvalumab to chemotherapy. So patients were randomized to either chemotherapy alone, chemotherapy with Durvalumab, followed by Durvalumab maintenance, and then in the third arm, we added Olaparib to the maintenance strategy. And we previously presented that it met its dual primary endpoints of progression-free survival with improved PFS in Durva versus control, as well as in the Durva Olaparib arm versus control...
So just to kind of level set, so DUO-E was a randomized phase three placebo-controlled trial that was looking to add immuno-oncology agent Durvalumab to chemotherapy. So patients were randomized to either chemotherapy alone, chemotherapy with Durvalumab, followed by Durvalumab maintenance, and then in the third arm, we added Olaparib to the maintenance strategy. And we previously presented that it met its dual primary endpoints of progression-free survival with improved PFS in Durva versus control, as well as in the Durva Olaparib arm versus control. Now, interestingly, when we teased those data out, it seemed like the Durva was the most important part for the mismatch repair deficient population. And conversely, the mismatch repair proficient population was the group that benefited the most from the addition of Olaparib. So that’s led to global regulatory approvals of both Durva with chemotherapy and Durva Olaparib in maintenance in that mismatch repair proficient group. So with all that being said, this was our interim overall survival analysis at our data cut two. And what we saw was a not statistically significant, but very clinically meaningful improvement in overall survival in both arms. When we looked at the Durva arm, it improved median overall survival compared to control by about a 15% reduction in the hazard of death. But interestingly, the Durva Olaparib arm reduced that by 23%. Now, what does that mean? When we look at the medians, there was an 11.5 month survival benefit for the population that received Durva and Olaparib compared to control. 11.5 months additional survival. So again, did not meet the statistical cutoff because we’re splitting the alpha, but is a very clinically meaningful benefit. We did tease it out by mismatch repair deficiency and mismatch repair proficiency. So in the mismatch repair deficient group, again, Durva was very, very, very active, 43% reduction in the risk of death as compared to control in that population that has the biomarker. And you’ll remember that I previously said that the addition of Olaparib didn’t offer much for progression-free survival in this mismatch repair deficient population. But interestingly, from an overall survival benefit, there was 57% reduction in the hazard of death in that mismatch repair deficient group. So this is something we’re gonna have to explore further. And then finally, when we looked at mismatch repair proficient, it was that Durva Olaparib group that had the biggest impact with a 15% reduction in the hazard of death and a median eight months gain in overall survival. So we were very excited about that. And then just to talk about toxicity, we didn’t see any new safety signals. The toxicity we see is very much related to the individual components with the highest grade three toxicity in things like anemia, neutropenia, you know, that type of thing, but a very well tolerated group.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.